MedicalResearch.com Interview with:
Elias Jabbour, MD
MD Anderson Cancer Center
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Inotuzumab is active in relapsed or refractory (R/R) acute lymphoblastic leukemia (R/R ALL). The addition of low intensity chemotherapy may further improve outcome.
ORR around 80%. Median survival 11 months. Better results obtained in Savage 1. Superior outcome when compared to historical cohort treated with inotuzumab monotherapy
MedicalResearch.com: What should readers take away from your report?
Response: Combining inotuzumab with low intensity chemotherapy is safe and effective and is superior to monotherapy with inotuzumab (11 months vs 6 months survival).
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
- Confirming these findings in a randomized phase 3 trial.
- Exploring lower dose of inotuzumab with the aim to reduce the rate of veno-occlusive disease
- Exploring the sequential combination of inotuzmab and Blinatumomab.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O’Brien S, Kantarjian H.
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic LeukemiaA Phase 2 Clinical Trial. JAMA Oncol. Published online August 31, 2017. doi:10.1001/jamaoncol.2017.2380
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.